Healthtech firm Huma and consultancy Atos have entered into a five-year strategic global partnership to shift healthcare and clinical trials from hospital to home.
The partnership focuses on Huma’s digital ‘hospital at home’ which helps remotely manage and monitor patients by tracking symptoms, vital signs, and deterioration by using real-time health data from smartphones.
The platform is already used in the US and across Europe for illnesses ranging including atrial fibrillation, diabetes and Covid-19.
The partnership also includes investment by Atos worth up to €20m dedicated to development of the platform and its promotion which will be split across research and development, dedicated consulting and sales personnel.
The investment in R&D will fast-track integration of the Huma platform with other clinical platforms and develop a dedicated video module.
Dan Vahdat, CEO and founder of Huma, said the partnership with Atos would allow it to offer services at scale, anywhere in the world.
“This partnership takes us to a new league – we have already shown that we can create a service for a new disease area in a matter of weeks, as we did during the pandemic, and that we can go live with over 100 clinics in a day,” he said.
Robert Vassoyan, head of health and life sciences business at Atos, added: “We have great excitement about this partnership, as we are convinced that Atos and Huma can drive a systemic shift from reactive to proactive models of care.
“Huma is the company we’ve been looking for in this important mission that resonates with each of us personally as we seek to improve the lives of our family, friends, neighbours and society. This is a partnership worthy of the mission.”
